BURLINGAME, Calif.--(BUSINESS WIRE)--Humanigen, Inc., (HGEN) (Humanigen), a clinical stage biopharmaceutical company focused on preventing and treating cytokine storm with lenzilumab, the companys proprietary Humaneered anti-human granulocyte macrophage-colony stimulating factor (GM-CSF) monoclonal antibody, announced that the Brazilian regulatory agency, Anvisa, has granted permission to commence a Phase III study of lenzilumab in patients with COVID-19 in Brazil.
This study, now set to begin recruiting patients in Brazil, follows the same protocol approved by the US Food and Drug Administration in April a multicenter, randomized, placebo-controlled, double-blinded clinical trial focused on hospitalized severe and critical adult COVID-19 patients at high risk of disease progression. Humanigen is working with Clinical Trial & Consulting (CTI), recently named the top global contract research organization, to conduct this trial in Brazil.
Cameron Durrant, MD, MBA, chief executive officer of Humanigen, said, COVID-19 is a global crisis and we are committed to offering assistance to patients across the world that are impacted by the pandemic. We hope that expanding the study of lenzilumab to research centers in Brazil, a country with surging rates of COVID-19, will offer patients much needed access to a leading COVID-19 therapeutic candidate.
Currently, Brazil has the second highest reported rates of COVID-19 infection in the world, second only to the US.
Access to clinical trials is critical for healthcare providers in the fight against COVID-19, remarked Timothy Schroeder, chief executive officer of CTI. We are proud to collaborate with our colleagues at Humanigen to extend the reach of the Phase III study of lenzilumab and bring a potential treatment option to those in need.
More details on Humanigens programs in COVID-19 can be found on the companys website at http://www.humanigen.com under the COVID-19 tab, and details of the US Phase III potential registration study can be found at clinicaltrials.gov using ClinicalTrials.gov Identifier NCT04351152.
About Humanigen, Inc.
Humanigen, Inc. is developing its portfolio of clinical and pre-clinical therapies for the treatment of cancers and infectious diseases via its novel, cutting-edge GM-CSF neutralization and gene-knockout platforms. We believe that our GM-CSF neutralization and gene-editing platform technologies have the potential to reduce the inflammatory cascade associated with coronavirus infection. The companys immediate focus is to prevent or minimize the cytokine release syndrome that precedes severe lung dysfunction and ARDS in serious cases of SARS-CoV-2 infection. The company is also focused on creating next-generation combinatory gene-edited CAR-T therapies using strategies to improve efficacy while employing GM-CSF gene knockout technologies to control toxicity. In addition, the company is developing its own portfolio of proprietary first-in-class EphA3-CAR-T for various solid cancers and EMR1-CAR-T for various eosinophilic disorders. The company is also exploring the effectiveness of its GM-CSF neutralization technologies (either through the use of lenzilumab as a neutralizing antibody or through GM-CSF gene knockout) in combination with other CAR-T, bispecific or natural killer (NK) T cell engaging immunotherapy treatments to break the efficacy/toxicity linkage, including to prevent and/or treat graft-versus-host disease (GvHD) in patients undergoing allogeneic hematopoietic stem cell transplantation (HSCT). Additionally, Humanigen and Kite, a Gilead Company, are evaluating lenzilumab in combination with Yescarta (axicabtagene ciloleucel) in patients with relapsed or refractory large B-cell lymphoma in a clinical collaboration. For more information, visit http://www.humanigen.com.
About CTI Clinical Trial and Consulting Services
CTI Clinical Trial and Consulting Services is a global, privately held, full-service contract research organization (CRO) recently named #1 CRO in the world for quality, delivering a complete spectrum of clinical trial and consulting services throughout the lifecycle of development, from concept to commercialization. CTIs focused therapeutic approach provides pharmaceutical, biotechnology, and medical device firms with clinical and disease area expertise in rare diseases, regenerative medicine/gene therapy, immunology, transplantation, nephrology, hematology/oncology, neurology, infectious diseases, hepatology, cardiopulmonary, and pediatric populations. CTI also offers a fully integrated multi-specialty clinical research site that conducts phase I-IV trials. CTI has a passion for helping life-changing therapies succeed in chronically and critically ill patient populations. With clinical trial experience across 6 continents, CTI partners with research sites, patients, and sponsors to fulfill unmet medical needs. CTI is headquartered in the Greater Cincinnati, OH area, with operations across North America, Europe, Latin America, and Asia-Pacific. For more information visit http://www.ctifacts.com.
Forward-Looking Statements
This release contains forward-looking statements. Forward-looking statements reflect management's current knowledge, assumptions, judgment and expectations regarding future performance or events. Although management believes that the expectations reflected in such statements are reasonable, they give no assurance that such expectations will prove to be correct and you should be aware that actual events or results may differ materially from those contained in the forward-looking statements. Words such as "will," "expect," "intend," "plan," "potential," "possible," "goals," "accelerate," "continue," and similar expressions identify forward-looking statements, including, without limitation, statements regarding our expectations surrounding our ongoing and anticipated clinical trial activities in the United States and Brazil and our operational, research, development or commercialization activities for lenzilumab and the other product candidates in our current pipeline. Forward-looking statements are subject to a number of risks and uncertainties including, but not limited to, the risks inherent in our lack of profitability and need for additional capital to conduct the Phase III study and grow our business; our dependence on partners to further the development of our product candidates; the uncertainties inherent in the development and launch of any new pharmaceutical product; the outcome of pending or future litigation; and the various risks and uncertainties described in the "Risk Factors" sections and elsewhere in the Company's periodic and other filings with the Securities and Exchange Commission.
All forward-looking statements are expressly qualified in their entirety by this cautionary notice. You should not place undue reliance on any forward-looking statements, which speak only as of the date of this release. We undertake no obligation to revise or update any forward-looking statements made in this press release to reflect events or circumstances after the date hereof or to reflect new information or the occurrence of unanticipated events, except as required by law.
The rest is here:
Humanigen Expands Phase III Study of Lenzilumab in COVID-19 to Brazil - Business Wire
- Stem cells on the ballot - Science Magazine - January 14th, 2021
- 2021 Startups to Watch: Ronawk's T-Blocks stack the future of stem cell research in an Olathe lab - Startland News - January 14th, 2021
- Towards a Cure: Carleton Research Team Working on Stem Cell Therapy to Reverse Type 1 Diabetes - Carleton Newsroom - January 14th, 2021
- Stem Cell Assay Market | Know the aspects that will serve as game-changers for the market - BioSpace - January 14th, 2021
- Center for cell and gene therapy to open next year - Harvard Gazette - January 14th, 2021
- Covid-19 Impact On Autologous Stem Cell and Non-Stem Cell Based Therapies Market 2020 Booming So Rapidly by 2027 | Fibrocell Science, Inc., Genzyme... - January 14th, 2021
- Jasper Therapeutics and Graphite Bio Announce Collaboration to Evaluate JSP191 as Conditioning Regimen for Novel Gene Replacement Therapy in Patients... - January 14th, 2021
- PureTech Founded Entity Vor Announces FDA Clearance of IND Application for VOR33 - Business Wire - January 14th, 2021
- Global Research Antibodies and Reagents Market Report 2020-2027: Significant Opportunities from Emerging Asia-Pacific and Latin-American Markets -... - January 3rd, 2021
- Stem Cell Manufacturing Market Size 2020 Industry Analysis, Key Players, Growth Prospects, Revenue, Production, New Development, Business Share,... - January 3rd, 2021
- Stem Cell Cartilage Regeneration Market : Revenue, Growth, Business Outlook & Forecast 2020-2029 - PharmiWeb.com - January 3rd, 2021
- Global Tissue and Organ Transplantation Market to Surpass US$ 25.6 Billion by 2027, Says Coherent Market Insights (CMI) - Business Wire - January 3rd, 2021
- Viral Clearance Market Is Expected To Reach USD 724.5 Million By 2023 From An Estimated USD 271.2 Million In 2018, At A CAGR Of 21.7% - LionLowdown - December 28th, 2020
- Biobank Market Industry Network, Key Vendors, Growth Analysis, Size, Share, Revenue Strategies and Forecast Report 2020-2026 | Coherent Market... - December 28th, 2020
- Global Neural Stem Cells Market 2020-2026 updated Report with the latest scenarios based on the global COVID-19 Pandemic - Farming Sector - December 24th, 2020
- Organ and Tissue Transplantation and Alternatives - GlobeNewswire - December 24th, 2020
- Comprehensive Report on Animal Stem Cell Therapy Market 2021 | Size, Growth, Demand, Opportunities & Forecast To 2027 | ANIMAL CELL THERAPIES,... - December 22nd, 2020
- Canine Stem Cell Therapy Market Analysis, Growth by Top Companies, Trends by Types and Application, Forecast Analysis to 2026 - Factory Gate - December 22nd, 2020
- Adipose Tissue-Derived Stem Cells (ADSCS) Market Size Is Expected To Generate Huge Profits and Competitive Outlook - The Courier - December 22nd, 2020
- Webinar on benefits of 3D cell culture techniques - SelectScience - December 22nd, 2020
- Soligenix Announces Topline Results from its Phase 3 Clinical Trial of SGX942 for the Treatment of Oral Mucositis in Head and Neck Cancer Patients -... - December 22nd, 2020
- The global cell isolation market size is projected to reach USD 15.0 billion by 2025 from USD 6.9billion in 2020, at a CAGR of 16.8% - GlobeNewswire - December 22nd, 2020
- Orchard Therapeutics Receives EC Approval for Libmeldy for the Treatment of Early-Onset Metachromatic Leukodystrophy (MLD) - GlobeNewswire - December 22nd, 2020
- Robert Gallo of the UM School of Medicine Institute of Human Virology and Global Virus Network Awarded Top Life Sciences and Medicine Prize from China... - December 22nd, 2020
- 3D Printing Industry review of the year: February 2020 - 3D Printing Industry - December 22nd, 2020
- Michigans Catholic bishops say 2 COVID-19 vaccines are OK morally but another is problematic - MLive.com - December 21st, 2020
- How Researchers Are Making Do in the Time of COVID-19 - The Wire Science - December 21st, 2020
- Stem cells in drug development - Nordic Life Science - December 19th, 2020
- Global Cell Culture Market by Product, Application, End-user and Region - Forecast to 2025 - PRNewswire - December 19th, 2020
- Glycostem and Ghent University sign license agreement on NK cell therapy technology | DNA RNA and Cells | News Channels - PipelineReview.com - December 19th, 2020
- EdiGene Expands Management Team by Appointment of Head of US Subsidiary Dr. Bo Zhang and Head of Business Development Dr. Kehua Fan - BioSpace - December 19th, 2020
- Global Primary Antibodies Market To Reflect Impressive Growth Rate by 2028||Leading Players-Thermo F - PharmiWeb.com - December 19th, 2020
- US gets more help in raging battle against COVID-19 as FDA authorizes Moderna vaccine, the second allowed for emergency use - USA TODAY - December 19th, 2020
- Diamyd Medical and Critical Path Institute announce data sharing collaboration to develop advanced drug development tools in type 1 diabetes -... - December 19th, 2020
- Skandalaris LEAP winners announced | WashU Fuse | Washington University in St. Louis - Washington University in St. Louis Newsroom - December 19th, 2020
- Creative Medical Technology Holdings Announces Successful Application of ImmCelz Immunotherapy for Treatment of Stroke - PRNewswire - December 17th, 2020
- Glycostem and Ghent University sign license agreement on NK cell therapy technology - PRNewswire - December 17th, 2020
- Creative Medical Technology Stock Price Increased 80.77%: Why It Happened - Pulse 2.0 - December 17th, 2020
- CRISPR Therapeutics Receives Grant to Advance In Vivo CRISPR/Cas9 Gene Editing Therapies for HIV - GlobeNewswire - December 14th, 2020
- EdiGene Expands Management Team by Appointment of Head of US Subsidiary Dr. Bo Zhang and Head of Business Development Dr. Kehua Fan - Business Wire - December 14th, 2020
- 3D Cell Culture Market by Scaffold Format, Products, Application Areas, Purpose, and Key Geographical Regions : Industry Trends and Global Forecasts,... - December 14th, 2020
- Akari Therapeutics Reports Third Quarter 2020 Financial Results and Highlights Recent Clinical Progress - GlobeNewswire - December 14th, 2020
- Researchers identify the origin of a deadly brain cancer - McGill Newsroom - December 14th, 2020
- Insights on the Global Stem Cell Therapy Market 2020-2024: COVID-19 Analysis, Drivers, Restraints, Opportunities, and Threats - Technavio - Yahoo... - December 9th, 2020
- Better education needed to give patients improved understanding of gene therapies, new review highlights - University of Birmingham - December 9th, 2020
- Extended Virus Shedding After COVID in Some Patients With Cancer - Medscape - December 9th, 2020
- Global Cancer Stem Cells Market to Boost with CAGR of 11.8% and Cross a Margin of $1,898.3 Million During the Covid-19 Outbreak Exclusive Report [150... - December 9th, 2020
- City of Hope Doctors Present Innovative Therapies to Better Treat Blood Cancers at American Society of Hematology Virtual Conference - BioSpace - December 9th, 2020
- New DARZALEX (daratumumab) Data from GRIFFIN Study Show Deeper and Longer Responses in Patients with Newly Diagnosed Multiple Myeloma - PRNewswire - December 9th, 2020
- CRISPR Therapeutics and Vertex Present New Data for Investigational CRISPR/Cas9 Gene-Editing Therapy, CTX001 at American Society of Hematology Annual... - December 9th, 2020
- Genetic engineering transformed stem cells into working mini-livers that extended the life of mice with liver disease - Albany Times Union - December 9th, 2020
- Researchers Trace the Origin of Blood Cancer to Early Childhood, Decades before Diagnosis - PRNewswire - December 9th, 2020
- Stem cells: past, present, and future | Stem Cell Research ... - December 8th, 2020
- Jasper Therapeutics Announces Data from First Transplant-naive Patient in Phase 1 Clinical Trial of JSP191 as Conditioning Agent in Patients with SCID... - December 8th, 2020
- After boosting gene therapy focus, Bayer signs up to new cell therapy pact with Atara - FierceBiotech - December 8th, 2020
- Data published in Cancer Research show Secarna Pharmaceuticals' LNAplus(TM) ASOs targeting metadherin significantly slow progression and metastasis of... - December 8th, 2020
- Europe Tissue Engineering Market Forecast to 2027 - COVID-19 Impact and Regional Analysis by Material Type, Applications, and Country -... - December 8th, 2020
- Allogene Therapeutics Presents Preclinical Data on ALLO-316 in Acute Myeloid Leukemia at the 62nd Meeting of the American Society of Hematology -... - December 8th, 2020
- Data Evaluating Tafasitamab with and without Lenalidomide in Combination with R-CHOP in Patients with DLBCL Presented at ASH 2020 - Business Wire - December 8th, 2020
- Incyte Announces Parsaclisib Treatment Results in High Rate of Rapid and Durable Responses in Patients with Relapsed or Refractory B-Cell Non-Hodgkin... - December 8th, 2020
- Enthera Pharmaceuticals Appoints Kazumi Shiosaki to Its Board of Directors and Lisa Olson to Its Scientific Advisory Board to Push Forward Company... - December 8th, 2020
- Meat-Tech Agrees to Acquire Cultured Fat Pioneer 'Peace of Meat' - PRNewswire - December 8th, 2020
- Actinium Reports 67 Percent Overall Response Rate in First Cohort in Actimab-A Venetoclax Combination Trial in Relapsed and Refractory AML at ASH -... - December 8th, 2020
- How do you donate stem cells? Donating cells can help treat cancer, blindness and other conditions - heres how - The Scotsman - December 6th, 2020
- Worldwide Stem Cell Therapy Market Insights to 2025 - Analysis and Forecasts - GlobeNewswire - December 6th, 2020
- Gene therapy gives man with sickle cell disease the chance for a better future - UCLA Newsroom - December 6th, 2020
- Gene-Editing Therapy CTX001 Reports Durable Effects for TDT, Sickle Cell Patients - MD Magazine - December 6th, 2020
- New Cedars-Sinai Biomanufacturing Center to Spur Cell Therapies - Newswise - December 5th, 2020
- Magenta Therapeutics and bluebird bio Announce a Phase 2 Clinical Trial Collaboration to Evaluate Magenta's MGTA-145 for Mobilizing and Collecting... - December 5th, 2020
- Global Single-cell Analysis Market Research Report 2020-2026 Featuring Major Players and Companies to Watch in the Future - PRNewswire - December 5th, 2020
- Cell Therapy Technologies Market | Extensive Information on a Plethora of Aspects Related to the Growth of the Market - BioSpace - December 5th, 2020
- Stem Cell Therapy Market Research Report Forecast to 2029 (Includes Business Impact of COVID-19) - Cheshire Media - December 5th, 2020
- Stem Cell Assay Market Overview, Development by Companies and Comparative Analysis by 2026 - Cheshire Media - December 5th, 2020
- Precision BioSciences Reports Positive Interim Results from PBCAR0191 Phase 1/2a Trial in Relapsed/Refractory (R/R) Non-Hodgkin Lymphoma (NHL) and R/R... - December 5th, 2020
- Cancer center is a contributor to 49 research studies at the 62nd American Society of Hematology Annual Meeting - Newswise - December 5th, 2020
- Bayer Launches Cell and Gene Therapy Platform to Maximize Recent Acquisitions - BioSpace - December 5th, 2020
- Chrysalis BioTherapeutics Receives $10.4 Million From BARDA to Continue Development of TP508 as a Nuclear Countermeasure - Business Wire - December 5th, 2020
- Reversing vision loss by turning back the aging clock - FierceBiotech - December 5th, 2020
- Clinical Trials Offer Opportunities to Change Practice to Improve Prevention and Treatment of Blood Disorders - PRNewswire - December 5th, 2020
- Research Antibodies and Reagents Market to Reach $6.32 Billion by 2027 With COVID-19 Impact, at a CAGR of 5.6% from 2020- Meticulous Research Analysis... - December 5th, 2020